Indivior Pharmaceuticals, Inc. (DELISTED) (INDV:DL)
36.28
+0.91
(+2.57%)
USD |
NASDAQ |
Nov 02, 16:00
Indivior Pharmaceuticals Shareholders Equity (Quarterly) : -60.00M for Sept. 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -60.00M |
| June 30, 2026 | -208.00M |
| March 31, 2026 | -144.00M |
| December 31, 2025 | -98.00M |
| September 30, 2025 | -207.00M |
| June 30, 2025 | -257.00M |
| March 31, 2025 | -285.00M |
| December 31, 2024 | -337.00M |
| September 30, 2024 | -167.00M |
| June 30, 2024 | -121.00M |
| March 31, 2024 | 10.00M |
| December 31, 2023 | 0.00 |
| September 30, 2023 | -24.00M |
| June 30, 2023 | 117.00M |
| March 31, 2023 | 72.00M |
| December 31, 2022 | 51.00M |
| September 30, 2022 | 227.00M |
| June 30, 2022 | 230.00M |
| March 31, 2022 | 232.00M |
| December 31, 2021 | 203.00M |
| September 30, 2021 | 161.00M |
| June 30, 2021 | 233.00M |
| March 31, 2021 | 164.00M |
| December 31, 2020 | 82.00M |
| Date | Value |
|---|---|
| September 30, 2020 | 80.00M |
| June 30, 2020 | 58.00M |
| March 31, 2020 | 39.00M |
| December 31, 2019 | 209.00M |
| September 30, 2019 | 252.00M |
| June 30, 2019 | 205.00M |
| March 31, 2019 | 133.00M |
| December 31, 2018 | 66.00M |
| September 30, 2018 | 48.00M |
| June 30, 2018 | -43.00M |
| March 31, 2018 | -101.00M |
| December 31, 2017 | -203.00M |
| September 30, 2017 | -74.00M |
| June 30, 2017 | -133.00M |
| March 31, 2017 | -211.00M |
| December 31, 2016 | -295.00M |
| September 30, 2016 | -382.00M |
| June 30, 2016 | -167.00M |
| March 31, 2016 | -230.00M |
| December 31, 2015 | -279.00M |
| September 30, 2015 | -289.00M |
| June 30, 2015 | -334.00M |
| March 31, 2015 | -408.00M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Supernus Pharmaceuticals, Inc. | 1.062B |
| Bristol Myers Squibb Co. | 23.40B |
| Eli Lilly & Co. | 40.27B |
| Ligand Pharmaceuticals, Inc. | 961.76M |
| Amneal Pharmaceuticals, Inc. | 531.26M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 1.332B |
| Total Liabilities (Quarterly) | 1.392B |
| Debt to Equity Ratio | -8.35 |
| Current Ratio | 0.6157 |
| Net Debt Paydown Yield | -0.64% |